US OptionsDetailed Quotes
MREO241220P4000
- 0.50
- 0.000.00%
15min DelayTrading Nov 25 15:44 ET
0.00High0.00Low
0.00Open0.50Pre Close0 Volume85 Open Interest4.00Strike Price0.00Turnover0.00%IV-3.40%PremiumDec 20, 2024Expiry Date0.62Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.77Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Mereo BioPharma Stock Discussion
Larger Image: tradingview.com...
$Mereo BioPharma (MREO.US)$
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
No comment yet